- Safety & Recalls
- Regulatory Updates
- Drug Coverage
- COPD
- Cardiovascular
- Obstetrics-Gynecology & Women's Health
- Ophthalmology
- Clinical Pharmacology
- Pediatrics
- Urology
- Pharmacy
- Idiopathic Pulmonary Fibrosis
- Diabetes and Endocrinology
- Allergy, Immunology, and ENT
- Musculoskeletal/Rheumatology
- Respiratory
- Psychiatry and Behavioral Health
- Dermatology
- Oncology
FDA actions in brief, March 2008
A summary of drugs and indications recently approved by FDA: Intelence, Alvesco Inhalation Aerosol, Moxatag, Humira, Asmanex, Tekturna HCT, Herceptin
Etravirine (Intelence, Tibotec) was approved for use with other antiretroviral agents for the treatment of HIV-1 infection in antiretroviral treatment-experienced adult patients who have evidence of viral replication and HIV-1 strains resistant to a non-nucleoside reverse transcriptase inhibitor (NNRTI) and other antiretroviral agents.
Ciclesonide (Alvesco Inhalation Aerosol, Nycomed) was approved for the maintenance and prophylactic treatment of asthma in adult and adolescent patients aged ≥12 years.
Once-daily amoxicillin extended-release tablets (Moxatag, MiddleBrook) were approved for the treatment of adults and pediatric patients aged ≥12 years with pharyngitis and/or tonsillitis secondary to Streptococcus pyogenes.
Mometasone inhalation powder (Asmanex Twisthaler, Schering-Plough) was approved for the maintenance treatment of asthma as a preventative therapy in patients aged 4 to 11 years.
Aliskiren/hydrochlorothiazide (Tekturna HCT, Novartis) was approved for the treatment of hypertension.
Trastuzumab (Herceptin, Genentech) was approved as adjuvant monotherapy for the treatment of early-stage HER2-positive breast cancer.
Drugs to Watch: Mental Health Conditions
April 11th 2024The FDA is reviewing two novel therapies: a psychedelic-assisted therapy for PTSD with a target action date of Aug. 11, 2024, and therapy for schizophrenia that does not directly block dopamine receptors with an action date of Sept. 26, 2024.
